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Background: Neuroglycopenia refers to a shortage of glucose in the brain resulting in neuronal
dysfunction and death if left untreated. Presumed neuroglycopenia has not been described in
horses.
Objective: To report neurological signs in horses with presumed neuroglycopenia as the result
of severe hypoglycemia.
Animals: Ninety horses (hours to 28 years of age) diagnosed with hypoglycemia (blood glucose
concentration < 75 mg/dL [< 4.2 mmol/L]).
Methods: Retrospective study. Electronic medical records were searched. Signalment, history,
complaint, clinical signs, laboratory findings including CSF analysis, electroencephalogram, clini-
cal or definitive diagnosis, and outcome were recorded. Kruskal-Wallis analysis of variance and
logistic regression were used to investigate association between blood glucose concentration
and data extracted. Statistical significance was set at P < 0.05.
Results: Thirty-eight and 52 horses had mild (50-74 mg/dL [2.8-4.1 mmol/L]), and severe hypo-
glycemia (< 50 mg/dL [< 2.8 mmol/L]), respectively. Most common causes of hypoglycemia
included liver and gastrointestinal (40%) disease, sepsis (33%), neoplasia (7%), and insulin-
induced (4%). Most common neurologic deficits included obtundation (100%), seizures (42%),
and disorientation (22%). CSF-glucose was severely low (mean 2.5 mg/dL [0.1 mmol/L], median
0 mg/dL). Paroxysmal discharges in support of seizures were identified in the occipital (visual)
and parietal (closest to temporal-auditory) cortical regions upon EEG examination (8/8 horses).
Conclusions and clinical importance: Neuroglycopenia is presumed to occur in horses as the
result of severe hypoglycemia. Subclinical seizures, and intermittent blindness and deafness of
cortical origin can occur. Severe altered state of consciousness and seizures can be observed at
a blood glucose cut-off value of < 42 mg/dL (< 2.3 mmol/L).
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1 | INTRODUCTION
Neuroglycopenia is a term that refers to a shortage of glucose in the
brain resulting in alteration of neuronal function.1,2 One of the most
common causes of neuroglycopenia is hypoglycemia.2 In human medi-
cine, hypoglycemia is usually defined by a blood glucose
(BG) concentration below 70 mg/dL (< 3.9 mmol/L).3 Neurogenic
(autonomic) and neuroglycopenic symptoms occur in humans with
hypoglycemia.4–6 Neurogenic symptoms result from the physiologic
response to hypoglycemia by the autonomous nervous system.4
These include tremors, palpitations, anxiety, sweating, tachycardia,
hunger, and paresthesias.4 Neuroglycopenic symptoms are related to
Abbreviations: BG, blood glucose; CSF, cerebrospinal fluid; CSF-G, CSF glucose;
ECG, electrocardiogram; EEG, electroencephalogram; IGF, insulin growth factor;
NE, neonatal encephalopathy; NICTH, non-islet cell tumor-induced
hypoglycemia
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deprivation or profound low glucose concentration in the brain, which
manifest as confusion, sensation of warmth, blurred speech, fatigue,
cognitive failure, seizures, coma, and death if unattended.3,4 During
the early stage of neuroglycopenia, cortical dysfunction might only be
recognized through a systematic cognitive testing.5,7 Cerebral cortical
dysfunction has been recorded when BG concentration is 36 mg/dL
(2 mmol/L) or less in humans and rats.1,2 At that low glucose level,
brain glucose concentration was reported to be close to zero.1,2 Mea-
surement of glucose concentration in cerebrospinal fluid (CSF) might
aid to investigate glucose concentration in the brain.8,9 Low glucose
concentration in CSF is termed hypoglycorrhachia and is most com-
monly associated with infection (mainly bacterial meningitis) but other
causes such as stroke, malignancy, neurosarcoidosis, and severe hypo-
glycemia are associated with low CSF glucose concentrations.10,11
The effects of hypoglycemia on brain function through electroen-
cephalography (EEG) have been studied in patients with and without
insulin dependent diabetes.2,12,13 Through the collection of serial
blood samples, it was determined that blood glucose concentration
above 54 mg/dL (3 mmol/L) did not cause alterations in EEG activity.2
Cortical neuronal dysfunction was shown as an abrupt decrease in
alpha activity with a concomitant increase in theta activity at a median
blood glucose concentration of 36 mg/dL (2 mmol/L).2 Further,
changes in EEG activity appear and disappear within a narrow range
of blood glucose concentrations.2 However, there is variability among
individuals manifesting neurologic dysfunction and EEG alterations
associated with hypoglycemia.14 In addition to hypoglycemia, alter-
ations in glucose transport, metabolism, and storage of glycogen can
cause or contribute to low glucose concentrations in the brain.9,15
Hypoglycemia has been reported in horses and defined as a BG con-
centration below 75 mg/dL (< 4.2 mmol/L).16,17 Although seizures
associated with hypoglycemia have been sporadically reported in vet-
erinary medicine, comprehensive clinical descriptions of the effects of
hypoglycemia on neurologic findings, documentation of hypoglycor-
rhachia and presumed neuroglycopenia and its associated electroen-
cephalographic findings have not been reported in horses.18–21
Further, there are no studies correlating low glucose concentrations in
blood and CSF in equine medicine.22,23 Therefore, the objective of the
study was to report neurological signs in horses with severe hypogly-
cemia. Furthermore, glucose concentration in CSF and EEG findings
were reported when available. Our testing hypothesis was that hypo-
glycorrhachia and presumed neuroglycopenia manifested as severe
neurologic dysfunction occur in horses with severe hypoglycemia.
2 | MATERIALS AND METHODS
2.1 | Animals
Electronic medical records from the William R. Pritchard Veterinary
Medical Teaching Hospital at the University of California at Davis
were searched using the words hypoglycemia, disorientation, insulin,
obtundation, stupor, coma, and seizures from the years 2000 to 2018.
Medical records were reviewed for the evaluation and definition of
state of consciousness, described as quiet, lethargic or obtunded (dull
but responsive to stimuli [e.g. non-painful tactile, visual, auditory]),
stupor (recumbent horse requiring strong painful stimuli for any corti-
cal response [perception or awareness, not reflex] to occur), and coma
(lack of any cortical response regardless of intensity of stimuli). Horses
of any breed, sex, and age with documented hypoglycemia at admis-
sion or at any time (if intermittent, recurrent, or as the result of insulin
therapy) during hospitalization were considered for the study. For this
study, hypoglycemia was defined as a BG concentration below
75 mg/dL (< 4.2 mmol/L), and severe hypoglycemia below 50 mg/dL
(< 2.8 mmol/L). Signalment, presenting complaint, physical and labora-
tory parameters, clinical or definitive diagnosis, and outcome were
recorded. When available, glucose concentration in cerebrospinal fluid
(CSF) was recorded. Measurement of CSF-glucose was done within
5 minutes after collection.
2.2 | Electroencephalography
An EEG to assess cortical activity during hypoglycemia was also
recorded if available. The examination consisted of an electroenceph-
alogram, electrooculogram (EOG), electrocardiogram (ECG), and respi-
ratory monitoring. A Nihon Kohden digital wireless EEG system
(Neurofax Wireless Input 1000A, Nihon Kohden America Inc., Foothill
Ranch, CA) with integrated video was used to obtain all standard EEG,
EOG, and ECG recordings. Electrode nomenclature and placement
was based from a modified human 10-20 system and described in
horses previously.24,25 Needle electrodes were placed subcutaneously
in the scalp of horses for the recording of the EEG as described else-
where.25 In brief, subcutaneous needle electrodes were placed in the
prefrontal (2 electrodes), frontal (3), central (3), parietal (3) and occipi-
tal (2) regions. Additional electrodes included 1 that served as a
ground (between the 2 prefrontal electrodes, 1 in the intercanthus
region and 1 at the base of each ear to evaluate for ear movement
artifacts on the EEG. Concurrently, an electrooculogram (2 subcutane-
ous electrodes per eye, 1 each in the upper and lower eyelids), elec-
tromyogram (2 subcutaneous electrodes located in the splenius
muscle), and electrocardiogram (1 subcutaneous electrode in the
region of the left heart base and 1 at the left heart apex) were also
performed. A bipolar montage (rostral to caudal and transverse) was
used with sensitivities set for recording as described.24,25 Thirty to
forty minutes of EEG recordings were obtained. The data obtained
was thoroughly examined from EEG tracings and simultaneous video
of the horse under study. The EEG study was approved by an animal
care and use protocol from our institution and clients consented to
perform an EEG.
2.3 | Statistical Analysis
Descriptive statistics are presented as mean, standard deviation,
median, and range. To assess if neurologic status (e.g. state of con-
sciousness, seizures), clinical diagnosis (e.g. sepsis, liver disease, and
others), and outcome (survival vs non-survival) were associated with
serum glucose concentration, Kruskal-Wallis analysis of variance was
performed. Linear regression was used to evaluate the correlation
between blood and CSF-glucose. Logistic regression was used to eval-
uate the association between BG concentration and clinical signs
(mental status, seizures); models were verified to be linear in the log
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odds of clinical sign occurrence. Receiver operating characteristic
curve analysis was performed to determine the cut-off for blood glu-
cose concentration that maximized the percentages of correctly clas-
sified cases with mild and severe neurologic signs. Statistical
significance was set at P <0.05.
3 | RESULTS
3.1 | Horses
Ninety horses had hypoglycemia (BG 0-74 mg/dL [0-4.1 mmol/L]) at
admission or intermittently during hospitalization. Based on age, the
following groups were identified: 1) neonatal foals defined as foals up
to 10 days of age (N = 35), 2) foals 11 days to one-month (N = 4), 3)
horses over one month up to 1-year (N = 4), and 4) adult horses, older
than 1 year (N = 47). The population in this study consisted of various
breeds including Quarter horses and related breeds (N = 33), Ameri-
can miniature horse (N = 17), Thoroughbred (N = 12), Arabian (N = 8),
Warmblood (N = 4), Pony (N = 4), Draft (N = 3), Morgan (N =3), Anda-
lusian (N = 2), and others (N = 1, each: Tennessee Walker, Standard-
bred, Mustang, and Selle Francais). There were 48 females,
17 geldings, and 25 intact males.
3.2 | Signalment by Age Group
Group 1: Neonatal foals were of Quarter horse (N = 16), Thorough-
bred (N = 6), American Miniature (N= 3), Pony and Draft (N = 2 each),
and other (N = 1 each, Morgan, Tennessee Walker) breeds. There
were 18 fillies and 17 colts. The mean and median age was 15 and
12 hours, respectively (SD 7 h, range 3 to 36 h). Group 2: Foals
11 days to one month old were of Quarter Horse (N = 3), and Andalu-
sian (N = 1). There were 2 fillies and 2 colts. The mean and median
age was 14.8 and 13 days, respectively (SD 4.3 d, range 12 to 21 d).
Group 3: Horses over one month up to 1 year of age were of Quarter
Horse (N = 2), and Arabian and American Miniature (N = 1 each)
breeds. There was one female and 3 colts. The mean and median age
was 6.3 and 6.5 months, respectively (SD 4.3 m, range 2 to 10 m).
Group 4: Horses older than 1 year of age were of American Miniature
(N = 13), Quarter Horse and related breeds (N = 12), Thoroughbred
(N = 6), Arabian (N = 5), Warmblood, Morgan, and Pony (N = 2 each),
and Draft, Andalusian, Standardbred, Mustang, and Selle Francais (N =
1 each) breeds. There were 28 females, 17 geldings, and 3 intact
males. The mean and median age was 12.7 and 11 years old, respec-
tively (SD 7.5 y, range 1.4 to 28 y).
3.3 | Glucose Concentration
For this section, glucose concentration will be reported as mg/dL. Of
90 horses with hypoglycemia, 38 had mild hypoglycemia (mean BG
62.5 [SD 7.4], median 63 [range 50-74] mg/dL), and 52 had severe
hypoglycemia (mean 27.3 [SD 15.9], median 31 [range 0-49] mg/dL)
(Table 1). There were 13 and 22 neonatal foals with mild (mean 61.3
[SD 7.7], median 63 [range 51-74] mg/dL) and severe (mean 23.5
[SD 15.8], median 18 [range 0-44] mg/dL) hypoglycemia, respectively.
One foal less than a month of age had a BG concentration of TA
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72 mg/dL; and 3 foals had 0, 6, and 25 mg/dL each. Four older horses
up to a year of age had mild hypoglycemia (51, 56, 69, and 70 mg/dL).
There were 21 and 26 adult horses with mild (mean 64.3 [SD 6.5],
median 67 [range 50-73] mg/dL) and severe (mean 33.1 [SD 14],
median 36 [range 7-49] mg/dL) hypoglycemia, respectively. See
Table 1 for further details on BG by age group. Glucose concentration
was measured in CSF collected from the atlanto-occipital cisterna in
20 horses (neonatal foals = 9 [mean 1.9 mg/dL, SD 3.5], non-neonatal
foals = 1 [0 mg/dL], and adults = 10 [mean 3.9 mg/dL, SD 5.9])
(Table 1). In these horses, CSF glucose concentration (mean 2.5
[SD 4.4], median 0 [range 0-12] mg/dL) was markedly lower
(P <0.001) than that of BG concentration (mean 14.6 [SD 15.5],
median 12 [range 0-63] mg/dL). A correlation (R = 0.81, P < 0.0001)
between low BG and CSF-glucose concentration was found. Cytology
(clear transparent, total protein < 100 mg/dL, total nucleated cells <
3/uL, proportion of small and large mononuclear cells within reference
range, and absence of neutrophils, eosinophils and basophils) and
other biochemical parameters (electrolytes, creatine kinase26) in CSF
were within reference range. Lactate in CSF was measured in
10 horses and had a mean of 2 mmol/L with a range from 1.2 to
4 mmol/L (reference range ≤ 2 mmol/L). These 10 horses had a sys-
temic lactate within reference range (≤ 2 mmol/L). There was no evi-
dence of bacteria in CSF.
3.4 | Clinical Diagnosis
Causes associated with hypoglycemia included sepsis (N = 30/90
horses), liver disease (N = 20/90), gastrointestinal disease (colic, colitis,
N = 16/90), hypertriglyceridemia (triglycerides 237-1415 mg/dL,
reference 9–41 mg/dL for adult horses) not secondary to GI or liver
disease (N = 8/47 adults), neoplasia (N =7/47 adults), neonatal
encephalopathy (N = 6/35), and others (N = 3/90) (Table 1). Three
others consisted of 2 neonatal foals tested positive for EHV1, and a
2-month old filly was diagnosed with immune-mediated myositis. The
most common diseases in these horses by age group are presented in
Table 1. In brief, the most common cause associated with hypoglyce-
mia in neonatal foals was sepsis (N = 25/35). Seven of these 25 foals
had concurrent neonatal encephalopathy. Neonatal encephalopathy
was presumed based on the development of altered neurological sta-
tus in foals 24 to 48 hours of age with no other apparent underlying
cause, and history of dystocia or rapid birth (< 20 minutes). Pathogens
identified on blood culture included Enterococcus sp., Actinobacillus sp.,
E. coli, and Proteus vulgaris. In adult horses, the most common disor-
ders associated with hypoglycemia included liver and gastrointestinal
disease (N = 15/47, each), and hypertriglyceridemia (N = 8/47) sec-
ondary to other causes (anorexia from respiratory and renal disease,
endocrinopathies). These 8 horses with hypertriglyceridemia were of
American Miniature breed, and in 4 had severe hypoglycemia and sei-
zures were presumed to be induced by the administration of insulin
therapy since dextrose administration corrected hypoglycemia and
prevented further seizures. Liver disease included failure due to cir-
rhosis of undetermined cause (N = 6/47 adults), pyrrolizidine alkaloid
toxicosis (N = 4/47 adults), cholangiohepatitis (N = 2, one young and
adult horse), acute hepatitis (N = 2/47 adults), Tyzzer’s (N = 2 non-
neonatal foals), and hepatic lipidosis (N = 1 adult horse). Seven adult
horses (mean age 13 years, range 4 to 22 years old) were diagnosed
with neoplasia or presumed neoplasia and intermittent episodes of
hypoglycemia. Identified neoplasia included renal undifferentiated car-
cinoma (N = 2 horses, BG 13 and 40 mg/dL each), renal tubular carci-
noma with GI carcinomatosis (BG 35 mg/dL), hemangiosarcoma
(BG 51 mg/dL), and lymphoma (BG 56 mg/dL). The 2 remaining horses
had masses suspected to be neoplasia based on ultrasound examina-
tion appearance (heterogeneous echogenicity, absence of a wall-off
cavitary mass containing fluid). Blood glucose in these 2 horses was
37 and 46 mg/dL, respectively. Five adult horses had sepsis. One
horse had disseminated Corynebacterium pseudotuberculosis infection,
and one other had Klebsiella sp. pneumonia. There was no significant
association between BG concentration and clinical diagnosis (probabil-
ity 0.0891).
3.5 | Neurologic Status
Reported neurological signs included altered state of consciousness
(N = 90/90), seizures (N = 38), disorientation (N = 20), intermittent
blindness (N = 12), and intermittent deafness (N = 10). Blindness was
observed as a lack of menace, bumping into objects and become star-
tled upon being touched. Deafness was identified as lack of response
or reaction to loud sound and being startled when approached. These
abnormalities were not always associated with altered state of con-
sciousness. State of consciousness was described as quiet, lethargic or
mildly obtunded (N = 24), severe obtundation (N = 61), stupor (N = 4),
and coma (N = 1). Neurological signs were defined as mild (quiet,
lethargic, or mildly obtunded) or severe (severe obtundation, stupor,
or coma, and seizures) (Figure 1). Overall, for all age groups combined,
BG was significantly different between animals showing mild and
those with severe neurological signs (P = 0.0001, Figure 1). Blood glu-
cose was inversely related to the probability of developing abnormal
mental status: for every 10 mg/dL (0.6 mmol/L) increase in glucose,
FIGURE 1 Blood Glucose concentration (mg/dL) in association with
severity of neurological signs. Mild (quiet, lethargic, or mildly
obtunded) or severe (severe obtundation, stupor, or coma, and
seizures) neurological signs
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the odds of abnormal mental status declined approximately 33% (odds
ratio of 0.656, 95% confidence interval = 0.473-0.909, P = 0.011).
Blood glucose was inversely related to the probability of developing
seizures: for every 10 mg/dL (0.6 mmol/L) increase in glucose, the
odds of developing seizures declined by approximately one-half (odds
ratio = 0.525, 95% confidence interval = 0.398-0.693, P < 0.001). For
neonates and horses older than 1 year of age, BG was significantly dif-
ferent between animals showing mild versus severe neurological signs
(P = 0.005 and P = 0.0011, respectively). A cut-off value of < 42 mg/dL
(< 2.3 mmol/L) correctly classified 100% of severely affected neuro-
logic cases and 96% of mildly affected cases, establishing a total cor-
rect classification of 98% of all cases. The area under the receiver
operating characteristic curve was 0.997 (95% confidence interval of
99.1-100%). Of the 38 horses in which seizures were reported, 81.6%
(N = 31/38: neonates N = 17/23, non-neonates N = 2/2, adults N =
12/12) had severe hypoglycemia. Seven of 12 horses with intermit-
tent blindness also had intermittent deafness. Six horses also had
other metabolic abnormalities that could have contributed to the
altered neurologic status such as hyperammonemia (N = 3: neonate =
1 [183 μg/dL], adults = 3, blood ammonia 70, 460 and 1217 μg/dL,
respectively; reference 5-59 μg/dL) and hypernatremia (N = 2 neo-
nates, sodium 156 and 183 mmol/L; reference 131-144 mmol/L). One
adult horse with mild hypoglycemia had collapsing episodes and hypo-
calcemia (Ca++ 0.63 mmol/L, reference ≥ 1.2 mmol/L). Recumbence
was reported in 33 horses: neonates = 25, non-neonates = 1, < 1 y =
1, adults = 6 horses.
3.6 | Electroencephalogram
Eight horses had an EEG performed while standing: 6 horses under
sedation (detomidine hydrochloride 0.01 mg/kg IV) and 2 unsedated
because of severe obtundation. These 8 horses had a mean BG of
29.6 mg/dL (range from 0 to 46 mg/dL). For illustration, the EEG
recording from a 5-year-old Thoroughbred filly with intermittent sei-
zures, blindness and deafness diagnosed with renal tubular carcinoma
is presented on Figure 2 (A-F). The EEG demonstrated paroxysmal
activity consisting of sharp waves (70-200 milliseconds), and spikes
(<70 ms) and waves supportive of seizure activity (Figure 2B-D). Par-
oxysmal activity was also observed in the absence of obvious clinical
manifestations of seizures and preceded clinical manifestations
(Figure 2C). Paroxysmal activity was observed in the occipital and
parietal cortical regions in all 8 horses, and in the frontal region in
5 horses. Paroxysmal activity was more profound and first observed in
the occipital cortical region. These EEG alterations became general-
ized if hypoglycemia was not treated promptly (Figures 2E-F). Electro-
encephalographic activity in the mare presented in the figures
returned to normal upon resuming IV dextrose administration (not
shown). Five of 8 horses had a CSF-glucose concentration of 0 mg/dL.
3.7 | Outcome
The overall hospital mortality rate for these 90 horses was 48%
(euthanasia = 28/90, died = 15/90 horses) (Table 2). Mortality
appeared to be higher in foals less than a one month of age (N =
20/39, 51.3%) than older foals and adults. By group, the case fatality
rate was 51, 50, 0, and 49% for the neonatal, non-neonatal foals, ≤
1 year, and adult horses, respectively (Table 2). The overall fatality rate
was 34 and 58% for horses with mild and severe hypoglycemia,
respectively (Table 2). However, a significant association between BG
concentration and outcome was not identified. Macroscopic postmor-
tem evaluation of the brain was available for 10 horses and did not
reveal alterations. Histological evaluation of the brain was not
available.
4 | DISCUSSION
This study reports horses with presumed neuroglycopenia based on
the presence of neurological signs such as altered state of conscious-
ness, seizures, disorientation, and intermittent blindness and deafness;
along with hypoglycemia which in 57% of horses was profound. Fur-
thermore, CSF glucose concentration was severely low and likely
reflecting glucose concentration in the brain as reported in human
medicine.9 Paroxysmal activity in support of seizures in the parietal
and occipital cortical region was seen in all horses on which an EEG
was performed. Therefore, this study also highlights the importance of
performing an EEG examination for the investigation of paroxysmal
activity in support of seizures even in the absence of clinical
manifestations.
Disorders causing hypoglycemia include those resulting in
increased glucose utilization and/or decreased glucose production,
altered metabolism, transport and storage.17 Examples of conditions
resulting in hypoglycemia in horses include sepsis, endotoxemia, liver
failure, illnesses impairing neonatal foals from nursing, and glycogeno-
sis such as glycogen branching enzyme deficiency in neonatal Quarter
Horses.16,17,27–29 Starvation and severe malnutrition are less common
causes of hypoglycemia. Delayed serum or plasma separation from
blood cells and hyperlipemia can result in falsely low BG concentra-
tion. Although hypoglycemia has been reported in equids of various
ages; neurological signs have been scarcely described.16,17
Neurogenic signs such as those described in humans with mild
hypoglycemia were rarely documented here.4,30 Observations of
tremors, palpitations, anxiety, sweating and others might have been
overlooked, difficult to interpret, or simply not reported in the medical
record. Early clinical manifestations of severe hypoglycemia in humans
include cognitive dysfunction.2,5 It has been reported that cognitive
function deteriorates in most diabetic patients at a BG concentration
of about 54 mg/dL (3 mmol/L) at which most patients are unaware of
hypoglycemia.2,5 Cognitive dysfunction in horses might be difficult to
assess and interpret. Instead, alterations in behavior such as disorien-
tation might have been an early manifestation of presumed neurogly-
copenia. Although glucose concentration in the brain was not
measured to define neuroglycopenia in our study; 100% of the horses
in which a CSF sample was collected (N = 20/20) had severe hypogly-
corrhachia. The report of intermittent blindness and deafness in a few
horses here was likely a manifestation of abnormal cortical activity
since these signs were intermittent and coincided with paroxysmal
activity based on EEG examination. However, alterations in the state
of consciousness can also result in intermittent lack of clinical
response to a menace and sound (clap) test. Neuroelectrodiagnostics
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such as visual and auditory evoked potentials were not performed in
these horses to further investigate the origin of those abnormalities.
Furthermore, intermittent blindness and deafness could be subtle and
not readily apparent unless a thorough and careful neurologic examina-
tion is performed at various times. Therefore, more horses with these
signs could have been missed. More severe clinical manifestations of
neuroglycopenia as those reported in humans (e.g. seizures, coma)4 are
more readily apparent than subtle abnormalities to the clinician dealing
with non-human species. In this study, 80.6% of the horses with
seizures had severe hypoglycemia. A BG concentration cut-off value of
42 mg/dL (2.3 mmol/L) was associated with the development of severe
neurologic dysfunction (severe alteration of the state of consciousness
and seizures, and severe hypoglycorrhachia (CSF-glucose mean 2.5
mg/dL [0.1 mmol/L]). Recumbence at admission was reported here in
39% of the horses of which the majority were neonatal foals (N =
25/33). However, these foals also had other disorders that could have
resulted in recumbence (e.g. sepsis, NE, severe liver disease).31–33
Recurrent hypoglycemic episodes can lead to blunting of mild
FIGURE 2 Electroencephalogram and simultaneous video recording of a 5-year-old Thoroughbred mare with renal tubular carcinoma. The following
figures depict EEG recordings of this filly at various stages of blood glucose manipulation during dextrose infusion. For all figures: odd numbers
represent left side, even numbers represent right side, FP = frontal polar, F = frontal, C = central, P = parietal, O = occipital, z = midline, A = auricular,
X2-X3 = ECG. Bar = 1 second, 50 microvolts. Note different scale for ECG. Figure 2A. Baseline EEG recording while the mare was on IV dextrose
administration. Heart rate = 30 bpm. Blood glucose concentration at the time of this recording was 83 mg/dL. Figure 2B. Electroencephalogram
showing slowing of waves throughout this epoch of 10 seconds. This recording was made within 1 minute of discontinuing IV dextrose
administration. Note sharp wave (arrow), spike and wave (oval) on occipital cortical region (O1-O2 channel) following cessation of IV dextrose drip.
Heart rate = 36 bpm. Figure 2C. Electroencephalogram showing multiple spikes and waves (throughout O1-O2) and sharp waves (*) noted on
occipital and parietal region. No IV dextrose administered during this 10 second epoch. Frontal polar channel is picking up eye movement artifacts:
eye movement (EM) and blink (B). Heart rate = 36 bpm. Figure 2D. Note increased paroxysmal discharges in occipital and parietal regions. No IV
dextrose administration during this recording. Heart rate = 42 bpm. Blood glucose concentration at the time of this recording was 44 mg/dL.
Figure 2E. Electroencephalogram showing paroxysmal activity mixed with movement artifact as the filly is having a clinical seizure manifested as
facial twitching and eye rolling. Blood glucose during this recording was 23 mg/dL. Heart rate = 36 bpm. Figure 2F. Electroencephalogram during
seizures. Note spread of paroxysmal activity, movement, and loss of electrodes. Note irregular ECG activity. After this recording, IV dextrose
administration was resumed and EEG activity returned to normal
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symptoms in people resulting in hypoglycemia unawareness and risk of
progressing to neuroglycopenic symptoms.14,34 In veterinary medicine,
mild hypoglycemic clinical manifestations might be more difficult to rec-
ognize and therefore missed. Furthermore, other disease processes can
result in similar non-specific clinical signs.
Hypoglycemia is a leading cause of neurological signs and
sequelae in infants with severe metabolic or infectious diseases.35
Cortical white matter hemorrhage, basal nuclei and thalamic injury,
and infarction in areas of the middle cerebral artery resulting in neuro-
logic symptoms and later neurodevelopmental impairment have been
documented in up to 94% of newborn infants with hypoglycemia.36,37
This injury has been dependent on duration and severity of hypogly-
cemia.36 Reference ranges for blood glucose concentration in neona-
tal foals have been reportedly higher than older foals and adult
horses.17,38 The reference range of blood glucose concentration for
neonatal foals at our institution is reported to be from 118 to
207 mg/dL (6.6 to 11.5 mmol/L). Glucose concentration in CSF can be
similar or slightly lower to that of BG in healthy adult horses; but it
could range from 40 to 70 mg/dL (2.2 to 3.9 mmol/L).22,23 Neonatal
and non-neonatal foals CSF glucose ranges from 65 to 110 mg/dL
(3.6 to 6.2 mmol/L).39 Although it is unknown at what level of hypo-
glycemia neonatal foals develop clinical manifestations; the authors
decided to follow Hollis definition of hypoglycemia (< 75 mg/dL [<
4.2 mmol/L]) for this study.16 Hypoglycemia has been reported to
occur in 29% of critically ill neonatal foals.16 This is because neonatal
foals are born with very low fat and glycogen stores, therefore any ill-
ness that interferes with getting adequate nutrition can result in hypo-
glycemia.40 Hypoglycemia in neonatal foals was associated with
nonsurvival to hospital discharge.16 Furthermore, extreme hypoglyce-
mia defined as blood glucose below 50 mg/dL (< 2.8 mmol/L) was
associated with sepsis, a positive blood culture and nonsurvival com-
pared to animals with higher blood glucose concentrations.17 In the
current study, the majority of neonatal foals were diagnosed with sep-
sis (N = 25/35), of which 17 had severe hypoglycemia. Thirteen (57%)
of 23 foals with severe hypoglycemia died or were euthanized. Similar
to other reports, foals from our study with severe liver disease such as
those with Tizzer’s developed severe hypoglycemia.33,41
Hypoglycemia is less common in adult horses compared to neonatal
foals and has been associated with liver failure, abdominal disease, criti-
cal illness, and neoplasia (hepatic and renal).17,18,42 In our study, the most
common causes associated with hypoglycemia in adult horses included
liver and gastrointestinal disease (33% each), followed by hypertriglyceri-
demia (18%). Hypoglycemia is the most common adverse effect of insu-
lin treatment in humans with type 1 diabetes and insulin-dependent
type 2 diabetes.43,44 Hypoglycemia and seizures as the result of insulin
therapy were also observed in our study (N = 4/8) and corrected with IV
dextrose administration and adjustment of insulin therapy. Renal adeno-
carcinoma, renal anaplastic carcinoma, papillary renal adenoma, hepato-
cellular carcinoma, cholangiocarcinoma, peritoneal mesothelioma, and
gastrointestinal stromal tumor have been associated with hypoglycemia
and presumed to be associated with the release of insulin growth-like
factor.17,18,42,45–49 In these horses, BG concentration was usually low
ranging from 13 to 65 mg/dL (0.7 to 3.6 mmol/L). Descriptions of
altered mentation and seizures were not always reported.18 In our
horses, intermittent to persistent hypoglycemia ranging from 13 to
56 mg/dL (0.7 to 3.1 mmol/L) was observed. All of these horses had
neurologic abnormalities (obtundation N = 6/7, seizures N = 4/7). Possi-
ble causes for hypoglycemia in these horses could have included inter-
mittent or persistent secretion of insulin growth-like factor by non-islet
cell tumors (non-islet cell tumor-induced hypoglycemia [NICTH]) and
paraneoplastic hypoglycemia as described in humans.50–53 Concentra-
tions of insulin-growth factors I and II for the documentation of NICTH
was not performed in these horses.53
Electroencephalography reflects the metabolic state of the brain.3
Hypoglycemic episodes have been associated with EEG changes that
could serve as predictors of severe hypoglycemia in humans.54,55 The
earliest abnormalities reported in mice included an increase in the
power of the delta and theta band relative to the power in the alpha
band.3 Reported EEG alterations include a decrease in alpha frequen-
cies and an increase in delta frequencies following with gradual aggra-
vation in EEG alterations as hypoglycemia progresses.55 Alpha/theta
ratio is a sensitive parameter for detecting changes in EEG during
hypoglycemia.55 Paroxysmal discharges supportive of epileptic activity
consist of sharp waves (70-200 milliseconds) and spikes (< 70 ms) and
waves.56 These discharges were observed in some horses despite the
lack of obvious clinical manifestations of seizures supporting subclini-
cal paroxysmal (epileptic) activity. However, altered behavior and
mentation could be manifestations of paroxysmal activity. As an
example, one mare on which an IV dextrose infusion was discontin-
ued, paroxysmal activity was observed prior to any clinical
TABLE 2 Outcome. N = horses, EU = euthanasia
AGE GROUP
Mild
Hypoglycemia
Severe
Hypoglycemia
TOTAL
HORSES (N)
NEONATES N = 12/35 N = 23/35 N = 35
OUTCOME Alive = 7
EU = 3
Died = 2
Alive = 10
EU = 5
Died = 8
Alive = 17
EU = 8
Died = 10
FATALITY
RATE (%)
42 57 51
> 10 DAYS -
1 MONTH
N = 1/4 N = 3/4 N = 4
OUTCOME EU = 1 Alive 2
Died = 1
Alive = 2
EU = 1
Died = 1
FATALITY
RATE (%)
100 33 50
> 1 MONTH -
1 YEAR
N = 0/4 N = 0/4 N = 4
OUTCOME Alive = 4 NA Alive = 4
FATALITY
RATE (%)
0 NA 0
> 1 - 28 YEARS N = 21/47 N = 26/47 N = 47
OUTCOME Alive = 14
EU = 7
Alive = 10
EU = 12
Died = 4
Alive = 24
EU = 19
Died = 4
FATALITY
RATE (%)
33 62 49
ALL HORSES N = 38/90 N = 52/90 N = 90
OVERALL
OUTCOME
Alive = 25
EU = 11
Died = 2
Alive = 22
EU = 17
Died = 13
Alive = 47
EU = 28
Died = 15
FATALITY
RATE (%)
34 58 48
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manifestations of seizures (Figure 2). Continuous EEG recording in this
mare showed an increase in paroxysmal activity that became general-
ized. Concurrently, the mare developed clinical manifestations of sei-
zure activity which subsided when IV dextrose infusion was resumed.
In humans, a topographic maximum of slow frequencies is found in
the frontal cortex at glucose levels of 50 to 60 mg/dL.2,55 During
more profound hypoglycemia (30 to 50 mg/dL [1.7 to 2.8 mmol/L])
there is a shift toward the posterior parts of the brain, and overall
changes in the EEG are more pronounced in the parietal-occipital and
temporal regions at blood glucose levels of 36 mg/dL (2 mmol/L).2,55
Generalized slowing is followed by spikes as the severity of hypogly-
cemia worsens.3 Alterations of the EEG during hypoglycemia might
not be identical in all patients but tend to be reproducible in each
patient.57 Similarly, EEG alterations in this study included slow fre-
quencies mainly in the occipital and parietal cortical areas in all horses
(N = 8/8) and in some horses (N = 5/8) slowing in the frontal cortex
was also observed. Alterations in the occipital (visual cortex) and pari-
etal (closest region to temporal-auditory cortex) cortical function
observed on EEG might explain the observed intermittent blindness
and deafness in these horses. Furthermore, blindness, deafness, and
EEG alterations appeared to resolve upon IV dextrose administration
(e.g. Mare in Figure 2). These 8 horses had severe hypoglycemia
(BG mean 29.6 [1.6 mmol/L], SD 17.6 mg/dL [1 mmol/L]). Generalized
slowing on EEG was followed by spikes as hypoglycemia worsened.
Five of these 8 horses had a CSF-glucose of 0 mg/dL.
In conclusion, presumed neuroglycopenia manifested as severe
altered state of consciousness and seizures can occur in horses with
severe hypoglycemia. Disorientation and intermittent blindness and
deafness of cortical origin sometimes occurred. Hypoglycemia was
more common in neonatal foals than in older foals and adults, and
commonly associated with sepsis. In adult horses, severe liver and/or
gastrointestinal disease were the most common causes of hypoglyce-
mia. Neoplasia must be considered as a possible cause of intermittent
hypoglycemia in adult horses. Caution must be taken when adminis-
tering insulin therapy to avoid insulin-induced hypoglycemia. A blood
glucose concentration cut-off value of < 42 mg/dL (< 2.3 mmol/L) was
associated with severe neurologic dysfunction and hypoglycorrhachia
in support of presumed neuroglycopenia. Hypoglycemia-induced EEG
alterations were observed in the occipital and parietal cortical regions
in horses with severe hypoglycemia. These EEG alterations became
more generalized if hypoglycemia was not treated promptly. This
study also highlights the importance of performing EEG for the inves-
tigation of abnormal cortical activity such as epileptic discharges
despite the lack of obvious clinical manifestations. Future studies
should include postmortem evaluation of the brain to document tissue
glucose concentration, and type, extent, and severity of neuronal
injury as the result of severe hypoglycemia.
[Correction added after first online publication 31 August 2018:
Last sentence removed.]
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